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Introduction: Gilbert syndrome (GS, OMIM 606785) is an autosomal recessive 
condition characterized by unconjugated hiperbilirubinemia in the absence of hemolysis 
or underlying liver disease due to the reduced activity of the uridine diphosphate-
glucuronosyltransferase (UGT1A1). This enzyme is mainly expressed in the liver and 
has an important role in the glucuronidation of bilirubin, 17β-estradiol, some therapeutic 
drugs and mutagenic xenobiotics. Absence or severe reductions of UGT1A1 activity are 
associated with Crigler-Najjar syndrome type I and type II, respectively. Heterozygous 
carriers of Crigler-Najjar syndrome also present a high incidence of mild 
hyperbilirubinemia, a feature of GS. 
Aim: This work investigated the effect of UGT1A1 variants on total bilirubin levels in 
Gilbert patients (n=45) and healthy controls (n=161).  
Methods: Total bilirubin levels were determined using a colorimetric method. Molecular 
analysis of exons 1-5 and two UGT1A1 promoter regions were performed by direct 
sequencing and automatic analysis of fragments. Five in silico methods predicted the 
effect of new identified variants.  
Results: A significant different allelic distribution, in Gilbert patients and in controls, was 
found for two promoter polymorphisms. Among patients, 82.2% were homozygous and 
17.8% heterozygous for the c.-41_-40dupTA allele; in control group, 9.9% were 
homozygous and 43.5% heterozygous for this promoter variant, while 46.6% (n=75) 
presented the [A(TA)6TAA]. For the T>G transition at c.-3279 promoter region, in 
patients, 86.7% were homozygous and 13.3% heterozygous; in control group, 33.5% 
were homozygous for the wild type allele, 44.1% were heterozygous and 22.4% 
homozygous for the mutated allele. The two polymorphisms were in Hardy-Weinberg 
equilibrium in both groups. Sequencing of UGT1A1 coding region identified nine novel 
variants, five in patients and four in controls. In silico analysis of these amino acids 
replacements predicted four of them as benign and three as damaging. 
 
Conclusions: We demonstrated that total bilirubin levels are manly determined by the 
TA duplication in the TATA-box promoter and by the c.-3279T>G variant. Alterations in 
the UGT1A1 coding region seem to be associated with increased bilirubin levels, and 
therefore with Gilbert Syndrome. 
 
